Peptide Comparison
Follistatin vs Follistatin 315
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 315 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 315 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Follistatin | Follistatin 315 | |
|---|---|---|
| Class | Myostatin-binding glycoprotein; anabolic | Follistatin isoform; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds and neutralizes myostatin and activin; promotes muscle growth | Circulating follistatin; heparin-binding; systemic myostatin inhibition |
| Route | SC injection | SC injection |
| Half-life | Variable by isoform | ~hours |
| Dosage (research) | 100-500 mcg SC daily (research) | 100-500 mcg SC daily |
| Evidence tier | Preclinical + Gene Therapy Trials | Preclinical |
| Research depth | 218 indexed | 43 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Activin off-target effects; fertility concerns; limited human data | Reproductive hormone interference |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Follistatin or Follistatin 315?
Follistatin has stronger documented evidence (Preclinical + Gene Therapy Trials) than Follistatin 315 (Preclinical) while both occupy the myostatin-inhibitor class. When clinical-evidence tier is the deciding factor, Follistatin is the safer pick. Follistatin 315 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Follistatin and Follistatin 315?
Follistatin is classed as Myostatin-binding glycoprotein; anabolic; Follistatin 315 is classed as Follistatin isoform; anabolic. Reported mechanism: Follistatin, Binds and neutralizes myostatin and activin; promotes muscle growth; Follistatin 315, Circulating follistatin; heparin-binding; systemic myostatin inhibition. Reported half-life: Follistatin, Variable by isoform; Follistatin 315, ~hours. Routes in published studies: Follistatin, SC injection; Follistatin 315, SC injection.
Which has stronger evidence, Follistatin or Follistatin 315?
Follistatin and Follistatin 315 sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Follistatin is graded Preclinical + Gene Therapy Trials, with 20 cited sources on its reference page and 218 indexed studies. Follistatin 315 is graded Preclinical, with 1 cited source on its reference page and 43 indexed studies.
Which is more accessible, Follistatin or Follistatin 315?
Neither Follistatin nor Follistatin 315 is an FDA-approved drug. Catalog status: Follistatin, Research Chemical; Follistatin 315, Research Chemical.
Are Follistatin and Follistatin 315 ever combined?
Follistatin and Follistatin 315 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…